Jazz Pharmaceuticals Acquires Actio Biosciences for Potential Epilepsy Treatment
Jazz Pharmaceuticals acquired Actio Biosciences in a $820 million upfront deal, with potential additional payments of up to $500 million based on regulatory and sales milestones. The acquisition targets ABS-1230, an experimental oral drug candidate for KCNT1-related epilepsy—a rare genetic disorder affecting around 2,500 U.S. patients—where current treatment options are limited. ABS-1230 has shown early clinical promise in reducing seizures and received multiple designations from the FDA including Fast Track, Rare Pediatric Disease, and Orphan Drug status. Jazz believes its ongoing Phase 1b/2a trial could serve as a registrational study for potential approval. The acquisition aligns with Jazz’s existing epilepsy franchise led by Epidiolex, which saw $292 million in Q2 sales. Jazz has strong financial backing to support the deal and future growth initiatives. In Q2 2026, it reported record revenue of $1.2 billion and raised its full-year guidance range to between $4.6 billion and $4.75 billion.
Tickers: $JAZZ
Topics: Biotechnology Drug Development Epilepsy Treatment Pharmaceuticals